Insilico Medicine

Insilico Medicine is a globally leading end-to-end generative AI-driven biotechnology company with a mission to extend healthy productive longevity for everyone by transforming drug discovery and development. The company leverages its proprietary Pharma.AI platform — spanning biology, chemistry, and clinical development — to significantly reduce the time and cost of bringing life-saving medications to patients. Insilico serves the pharmaceutical and life sciences industries, offering both an internal AI-driven drug discovery pipeline and software solutions for external partners in scientific research and sustainability.

Insilico Medicine operates as a fully integrated AI biotech, advancing a self-generated pipeline of novel drug candidates while also providing generative AI software tools to the broader scientific community. The company's core values center on patient-first priorities, transparency and integrity, and relentless innovation.

Core AI Platform: Pharma.AI

• Pharma.AI is Insilico's proprietary end-to-end generative AI platform, integrating capabilities across biology, chemistry, and clinical development to accelerate drug discovery and development.
• The platform is designed to rapidly and efficiently advance fully self-generated AI-driven drug discovery (AIDD) pipelines composed of novel drug candidates.
• Insilico is recognized as a globally leading company in terms of AIDD pipeline progress, using AI to create an entirely new AI-driven drug discovery pipeline from target identification through to clinical development.

Key Software Products and Modules

• Chemistry42 — A generative AI platform for small molecule drug design and chemistry-focused drug discovery workflows.
• Biology42 — An AI-powered suite addressing biological aspects of drug discovery, including disease modeling and target identification.
• Medicine42 — A module focused on clinical development and translational medicine applications within the Pharma.AI ecosystem.
• Science42 — A platform component supporting broader scientific research applications powered by generative AI.
• Large Language of Life Models (LLLMs) — Proprietary large language models trained on life sciences data to support drug discovery and biological research.
• LLM Assistant — An AI-powered assistant tool designed to support researchers in scientific workflows.
• PandaClaw — An agentic AI tool launched to empower biologists in therapeutic discovery, enabling autonomous AI-driven research tasks.

Therapeutic Pipeline

• Insilico maintains an active internal drug discovery pipeline with programs spanning multiple stages, including Phase II, Phase I, IND-enabling studies, lead optimization, hit-to-lead, and target identification.
• Several programs are available for licensing, reflecting the company's business development strategy alongside its internal development efforts.
• The pipeline covers a range of indications, with additional programs in active discovery stages.
• Notable recent milestones include a global R&D collaboration with Lilly, an expanded AI-driven CNS collaboration with Tenacia Biotechnology valued at up to US$94.75 million, and a partnership with ASKA Pharmaceutical to discover novel targets for women's health.
• Insilico's AI platforms enabled the discovery of a potent, selective, oral DGKα inhibitor to overcome checkpoint resistance, published in the Journal of Medicinal Chemistry.
• A strategic partnership with Liquid AI was announced to deliver lightweight scientific foundation models for drug discovery.

Scientific Approach and Research

• Insilico uses aging as a framework to identify disease, training AI to analyze large, multi-component datasets to identify novel targets and novel molecules.
• The company offers a Disease Modeling and Target Discovery Course, available for free enrollment, reflecting its commitment to scientific education.
• Insilico's Scientific Advisory Board includes Nobel Prize laureates such as Michael Levitt, PhD (Stanford professor, Nobel Prize in Chemistry 2013), who has highlighted the transformative potential of AI in protein folding and drug design.
• The company has built on decades of protein modeling research, integrating advances such as AlphaFold and OPUS-X into its AI-driven discovery workflows.

Global Presence and Partnerships

• Insilico Medicine operates globally with office sites and R&D talent in the United States, Greater China, Canada, and the Middle East.
• The company has established collaborations with 10 of the top 20 global pharmaceutical companies (by 2021 reported sales), as well as leading academic institutions and industry partners worldwide.
• Insilico has received strong support from globally leading financial and strategic investors, including Warburg Pincus, Qiming Venture Partners, WuXi AppTec, B Capital Group, Prosperity 7, OrbiMed, Deerfield, Pavilion Capital, Mirae Asset Capital, Lilly Asia Ventures, Eight Roads, Lake Bleu Capital, Baidu Ventures, and Sinovation Ventures.
• The company has been named to Fast Company's annual list of the world's most innovative companies, underscoring its industry recognition.

Insilico Medicine continues to redefine value delivery in AI-powered drug discovery, combining a robust internal pipeline with externally licensed software and broad industry collaborations to advance its mission of extending healthy longevity for patients worldwide.